Pilot trial of lithium treatment in mild cognitive impairment shows modest memory effects, informing larger confirmatory ...

Among adults with relapsing MS who received ublituximab, the annualized relapse rate continued to drop with up to 5 years of ...

Neurology has seen a surge in drug options, necessitating comparative effectiveness research to guide treatment decisions and address disparities in access and outcomes. Collaborative efforts between ...

Please provide your email address to receive an email when new articles are posted on . Treatment with tolebrutinib 60 mg for 12 weeks reduced new gadolinium-enhancing and new or enlarging T2 lesions ...

UAB startup continues promising global impact for functional neurological disorder treatment through telehealth ...

Messenger ribonucleic acid (mRNA)-based therapeutics and the potential of mRNA as a treatment for various conditions has been researched for decades. A key challenge remains finding a delivery system ...

Explore what is driving progress in neurological biomarker research today, from emerging technologies to clinical translation ...

Fenebrutinib significantly reduced the annualized relapse rate in patients with relapsing multiple sclerosis compared with teriflunomide.

Understanding the differences and similarities between neurological disorders and neurodegenerative diseases can be important when offering or accessing healthcare. It is also important for scientific ...

COLUMBIA — The University of South Carolina plans to build a highly specialized hospital promising “world-class treatment” and rehabilitation for strokes, dementia and other diseases affecting the ...

New Way Neurology is now open and serving patients at 100 Ridgeway St., Suite 2, in Hot Springs. The new practice is led by ...